|
|
Strategic Perspectives 2001: Diabetic Hypertension - Towards Aggressive, Individual and Holistic Treatment StrategiesPublished by: Datamonitor Published: Dec. 10, 2001 - 243 Pages Table of ContentsStrastegic Perspectives 2001: Diabetic Hypertension - Towards Aggressive, Individual and Holistic Treatment Strategies Scope Datamonitor insight into the diabetic hypertension market Key metrics INTRODUCTION DIABETES: A CV RISK FACTOR Diabetes overview Type 1 diabetes Type 2 diabetes Complications of diabetes Cardiovascular disease Microvascular complications DIABETIC HYPERTENSION: A LETHAL COMBINATION Relationship between hypertension and insulin resistance Type 1 diabetics Type 2 diabetics Obesity Race Mechanism of hyperinsulinemia induced hypertension: Increased risk associated with diabetic hypertension PATIENT POTENTIAL Prevalence of diabetes Methodology for determining prevalence of diabetes Forecast prevalence of diabetes to 2025 Forecast methodology for determining the prevalence of diabetes Prevalence of diabetic hypertension Methodology for determining the prevalence of diabetic hypertension Forecast prevalence of diabetic hypertension Forecast methodology for determining the prevalence of diabetic hypertension Prevalence of hypertension Methodology for determining the prevalence of hypertension Forecast prevalence of hypertension Forecast methodology for determining the prevalence of hypertension CLINICAL TRIAL REVIEW The evidence for aggressive treatment of diabetic hypertensives The UKPDS The HOT study Syst-Eur trial The market implications Clinical trial review of anti-hypertensives in diabetics ACE inhibitors: first line therapy? Beta blocker treatment in diabetics Angiotensin II receptor blockers Additional indications for AIIRBs set to fuel class growth Lack of head to head trial with ACE inhibitors AIIRBs: a second line therapy option? Combination therapy DEVELOPMENTAL COMPOUNDS Pipeline overview BMS should promote Vanlev (omapatrilat) for resistant hypertension Alteon: leading the way in multi-modal drugs? TREATMENT GUIDELINES National Kidney Foundation World Hypertension League National Heart Lung and Blood Institute (NHLBI) British Hypertension Society (BHS) National Institute for Clinical Excellence (NICE) in the UK OPINION LEADER INTERVIEWS Summary of opinion leader views ACE inhibitors - the therapy of choice in diabetic hypertensives Beta blockers - not contraindicated in diabetics and essential in combiantion therapy CCBs- very potent for lowering blood pressure, but reserved for 3rd/4th line therapy Diuretics - second line therapy of choice AIIRBs Single pill combinations - need to be available in the right doses Optimal combination therapy - it's a simple as ABC, 123! Unmet needs The future of therapy Selected quotes from opinion leader interviews Prof. Graham MacGregor interview transcript ACE inhibitors Beta blockers AIIRBs Future treatment Prof. Thomas Unger interview transcript ACE inhibitors Beta blockers AIIRBs Optimal combination therapy Future treatment Dr. Ron Smith interview transcript ACE inhibitors Beta blockers AIIRBs Optimal combination therapy Future treatment Dr. Ariel Reyes interview transcript ACE inhibitors Beta blockers AIIRBs Optimal combination therapy Future treatment Prof. Daniel Duprez interview transcript ACE inhibitors Beta blockers AIIRBs Optimal combination therapy Future treatment Dr. Atar interview transcript Introduction ACE inhibitors Beta blockers AIIRBs Optimal combination therapy Future treatment Dr. Massimo Ciavolella interview transcript ACE inhibitors Beta blockers AIIRBs Optimal combination therapy Future treatment Dr. Theodore Kotchen ACE inhibitors Beta blockers AIIRBs Optimal combination therapy Future treatment Anti-diabetic agents Dr. Gavin Russell ACE inhibitors Beta blockers AIIRBs Optimal combination therapy Future treatment Prof. Mario Maranhao interview transcript ACE inhibitors Beta blockers AIIRBs Optimal combination therapy Future treatment Prof. Isabel Coma-Canella interview transcript ACE inhibitors Beta blockers AIIRBs Optimal combination therapy Future treatment STRATEGIC FOCUS Commercial implications and recommendations Case studies Novartis Aventis GlaxoSmithKline Further opportunities APPENDIX References Table of tables List of figures (c) Datamonitor 2001. All Rights Reserved. AbstractThe diabetic segment of the hypertension market represents a large and growing patient sub-population, which is becoming increasingly attractive for companies marketing anti-hypertensives to penetrate successfully. Therefore, this report, which is largely based on indepth interviewes with 11 global opinion leaders, answers the following questions: * How important is diabetes as a CV risk factor and what is its relationship to hypertension? * What is the size of the diabetic hypertension market in each of the seven major markets and how will this be affected by the diabetes epidemic that is taking place? * What are the commercial implications of lowering blood pressure goals in diabetics? * To what extent are the microvascular diabetic complications (nephropathy, neuropathy and retinopathy) considered when prescribing therapy for diabetic hypertensives? * Do physicians believe that ACE inhibitors are renoprotective in diabetics and to what extent will the AIIRBs threaten the use of these agents at first line, following the recent PRIME and RENAAL results? * What is the role of diuretics, beta blockers and calcium channel blockers (CCBs) in diabetic hypertensives and what are the prevailing views among global opinion leaders regarding the controversies and issues that surround the treatment of diabetic hypertension? * What are the greatest unmet needs in the treatment of diabetic hypertension, what is the trade-off between efficacy and side effects and what is the most successful way for new compounds to penetrate this market? * In what direction will the treatment of diabetic hypertension move in the future and which companies will be in the best position to benefit from the expanding patient population?Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||